複雜性腹內感染、複雜性泌尿道感染、院內感染性肺炎

Cephalosporin Combination:
Ceftolozane is an inhibitor of penicillin-binding proteins. Tazobactam irreversibly inhibits some beta-lactamases.

Distribution:
Adults: Ceftolozane: 13.5 L; Tazobactam: 18.2 L. Protein binding:
Ceftolozane: 16% to 21%; Tazobactam: 30%. Half-life elimination:
Adults: Ceftolozane: ~3 to 4 hours; Tazobactam: ~2 to 3 hours. Metabolism:
Ceftolozane: Not metabolized; Tazobactam: Hydrolyzed to inactive metabolite. Excretion:
Ceftolozane: Urine (>95% as unchanged drug); Tazobactam: urine (>80% as unchanged drug).

Serious hypersensitivity to ceftolozane/tazobactam, piperacillin/tazobactam, other members of the beta-lactam class, or any component of the formulation.

>10%:Abdominal pain, diarrhea, Positive direct Coombs’ test, thrombocythemia , Increased serum transaminases, Fever.

Intra-abdominal infection: IV: 1.5 to 3 g every 8 hours in combination with metronidazole for 4 to 5 days.
Pneumonia, hospital-acquired or ventilator-associated: IV: 3 g every 8 hours for 7 days.
Serious infections: 1.5 to 3 g every 8 hours; 3 g every 8 hours should be used for pulmonary. Infections.
Urinary tract infection, complicated: 1.5 g every 8 hours for 5 to 14 days .

Intra-abdominal infection:
<18 years: IV: 20 mg ceftolozane/kg/dose every 8 hours in combination with metronidazole for 5 to 14 days; maximum dose: 1g ceftolozane per dose.
Urinary tract infection, complicated:
<18 years: IV: 20 mg ceftolozane/kg/dose every 8 hours for 7 to 14 days; maximum dose: 1g ceftolozane per dose.

CrCl 30 to 50 (mL/minute) : half the usual recommended dose.
CrCl 15 to 29 (mL/minute) : 1/4 the usual recommended dose.
CrCl <15 (mL/minute) : There are no dosage adjustments provided in the manufacturer's labeling.